AI Healthcare Stocks Merck, Amgen, and Johnson & Johnson Outperform
Artificial intelligence is increasingly becoming a practical tool in healthcare, moving beyond mere buzzwords to tangible applications in drug discovery and surgical procedures. This shift presents a unique opportunity as biotech and healthcare companies harness AI to expedite drug development, making it faster, cheaper, and more precise. The ongoing demand for healthcare ensures that these businesses remain integral to the economy, especially as they innovate and adapt to new technologies.
Among the top performers in this sector are Merck & Company, Amgen, and Johnson & Johnson, all of which are utilizing AI to enhance their operations while also providing dividends to investors. According to Barchart’s Stock Screener, these companies have shown remarkable stock performance, significantly outpacing the S&P 500.
Market Reading & Resources
Sponsor funding complete. Trade on.
Merck & Company, known for its medicines and vaccines, has seen its stock rise 42% this year, outperforming the S&P 500 by approximately 29 percentage points. The company is also expanding its AI capabilities through a partnership with Google Cloud, which supports its research and manufacturing processes. Additionally, Merck offers a forward annual dividend of $3.40, yielding about 2.17%. Analysts rate Merck as a “Moderate Buy,” indicating potential for further growth.
Amgen, another key player in the biotech space, focuses on developing treatments for various diseases, particularly cancer. The company is leveraging NVIDIA's technology to enhance its drug discovery processes. Amgen's stock has increased by 34% year-to-date, surpassing the market by around 21 percentage points. It also pays an annual dividend of $10.08 per share, translating to a yield of approximately 2.3%. Analysts have a consensus rating of “Moderate Buy” for Amgen, although its stock is nearing its high target price.
Johnson & Johnson, a well-known name in healthcare, is actively involved in innovative medical technologies, including AI initiatives aimed at optimizing surgical workflows. The company’s stock has risen 28% this year, outperforming the S&P 500 by 15 percentage points. Johnson & Johnson offers an annual dividend of $5.36 per share, yielding about 2%. Analysts also rate JNJ stock as a “Moderate Buy,” with a modest upside projected over the next year.
As healthcare continues to evolve, these companies exemplify how AI can drive innovation while providing steady dividends. For investors seeking exposure to both the healthcare sector and the AI boom, Merck, Amgen, and Johnson & Johnson present compelling opportunities worth exploring.




